A Certified Reference Material
Features
  • This product is qualified as a Certified Reference Material (CRM) that has been manufactured and tested to meet ISO/IEC 17025 and ISO 17034 international standards
  • This CRM has been characterized by metrologically valid procedures and may be used as a quantitative analytical reference standard
  • Certificate of analysis provides the certified property values and the associated uncertainties, including a statement of metrological traceability for the certified values
  • Bulk material is available for qualified institutions; please contact our sales department for pricing
Related Products
Research Tool(s)
11937Olanzapine
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Olanzapine (CRM)

A 1 mg/ml solution in acetonitrile

Item No. 40162

Safety Data Sheet (SDS) (PDF)
Synonyms
Synonyms
  • LY170053
Technical Information
Formal Name
2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
CAS Number
132539-06-1
Molecular Formula
C17H20N4S
Formula Weight
312.4
Formulation
A 1 mg/ml solution in acetonitrile
SMILES
CN(CC1)CCN1C2=NC3=CC=CC=C3NC4=C2C=C(C)S4
InChi Code
InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3
InChi Key
KVWDHTXUZHCGIO-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $94

    Add
    Cayman Chemical
    Forensic Lab Guide Wall Posters

    Discover our collection of drug identification, naming, and metabolism posters for your lab. We offer all of our posters at no cost to help support the forensic community.

    REQUEST YOURS
    Product Description

    Olanzapine (CRM) (Item No. 40162) is a certified reference material categorized as a thienodiazepine and an atypical antipsychotic.1 Olanzapine decreases immobility time in the forced swim test in non-stressed and prenatally-stressed rats.2 It prevents acute and chronic phencyclidine-induced deficits in cued reversal learning, as well as decreases the number of avoidances made in the conditioned avoidance response test, in rats.3,4 Olanzapine has been associated with intentional misuse in children and abuse in adolescents.5 Formulations containing olanzapine have been used in the treatment of schizophrenia and bipolar disorder. This product is intended for analytical forensic applications. This product is also available as a general research tool (Item No. 11937).

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Bymaster, F.P., Calligaro, D.O., Falcone, J.F., et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14(2), 87-96 (1996).

    2. Nowakowska, E., Kus, K., Ratajczak, P., et al. The influence of aripiprazole, olanzapine and enriched environment on depressant-like behavior, spatial memory dysfunction and hippocampal level of BDNF in prenatally stressed rats. Pharmacol. Rep. 66(3), 404-411 (2014).

    3. McLean, S.L., Neill, J.C., Idris, N.F., et al. Effects of asenapine, olanzapine, and risperidone on psychotomimetic-induced reversal-learning deficits in the rat. Behav. Brain Res. 214(2), 240-247 (2010).

    4. Ashby, D.M., Lapish, C.C., and Phillips, A.G. Stability of avoidance behaviour following repeated intermittent treatment with clozapine, olanzapine or D,L-govadine. Behav. Pharmacol. 26(1-2), 133-138 (2015).

    5. Merino, D., Gérard, A.O., Destere, A., et al. Antipsychotic abuse, dependence, and withdrawal in the pediatric population: A real-world disproportionality analysis. Biomedicines 10(11), 2972 (2022).